Scandipharm (US) targets bronchitis market
This article was originally published in Clinica
Executive Summary
Scandipharm (US) has received US FDA clearance to market its Flutter mucus removal device for patients with chronic bronchitis and bronchiectasis. The hand-held device, which was cleared for use by cystic fibrosis sufferers last August (see Clinica No 617, p 19), effectively shakes mucus from the air passages through vibrations caused by a moving steel ball.